BNTX:NSD-BioNTech SE (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 92.72

Change

+0.48 (+0.52)%

Market Cap

USD 21.93B

Volume

0.66M

Analyst Target

USD 79.79
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.70 (+0.35%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

+9.97 (+0.97%)

USD 110.51B
MRNA Moderna Inc

-5.20 (-3.58%)

USD 57.87B
ARGX argenx NV ADR

-1.34 (-0.35%)

USD 23.09B
ALNY Alnylam Pharmaceuticals Inc

+0.34 (+0.21%)

USD 20.25B
GMAB Genmab AS

-0.22 (-0.83%)

USD 18.17B
BGNE BeiGene Ltd

-3.80 (-2.28%)

USD 17.74B
RPRX Royalty Pharma Plc

-0.28 (-1.03%)

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.73 (-0.87%)

USD 15.32B
INCY Incyte Corporation

-0.58 (-0.93%)

USD 13.30B

ETFs Containing BNTX

MSGR 6.26 % 0.00 %

N/A

N/A
HVAX:CA 4.97 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 4.31 % 0.00 %

-0.12 (-0.79%)

USD 6.79M
GNOG:LSE Global X Genomics & Biote.. 4.05 % 0.00 %

-0.11 (-0.79%)

USD 6.38M
CURE:XETRA VanEck Genomics and Healt.. 4.03 % 0.00 %

-0.25 (-0.79%)

USD 6.79M
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-1.52 (-0.79%)

USD 1.15B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-0.88 (-0.79%)

USD 7.34B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.24 (-0.79%)

USD 0.09B
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

-0.44 (-0.79%)

USD 0.14B
VIDI Vident International Equi.. 0.00 % 0.63 %

-0.15 (-0.79%)

USD 0.38B
GERM ETFMG Treatments Testing .. 0.00 % 0.00 %

-0.35 (-0.79%)

USD 0.01B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-9.70 (-0.79%)

USD 5.63M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

-0.19 (-0.79%)

USD 5.63M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.15% 42% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.15% 42% F 32% F
Trailing 12 Months  
Capital Gain -14.49% 57% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.49% 57% F 36% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 72.51% 90% A- 94% A
Dividend Return 72.51% 90% A- 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 151.59% 16% F 10% F
Risk Adjusted Return 47.83% 92% A 79% B-
Market Capitalization 21.93B 99% N/A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.